Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Affimed N.V. (AFMD) - free report >>
DZS Inc. (DZSI) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Affimed N.V. (AFMD) - free report >>
DZS Inc. (DZSI) - free report >>
Image: Bigstock
New Strong Sell Stocks for September 13th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Affimed N.V. (AFMD - Free Report) is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 84.2% downward over the last 30 days.
DZS Inc. (DZSI - Free Report) provides network access solutions and communications platforms. The Zacks Consensus Estimate for its current year earnings has been revised 13% downward over the last 30 days.
Esports Entertainment Group, Inc. (GMBL - Free Report) is a licensed online gambling company. The Zacks Consensus Estimate for its current year earnings has been revised 1.9% downward over the last 30 days.
Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Zacks Consensus Estimate for its current year earnings has been revised 20.4% downward over the last 60 days.
View the entire Zacks Rank #5 List.